ABO incompatible renal transplantation: a paradigm ready for broad implementation.
The requirements for potent immunosuppression coupled with the formidable risk of irreversible antibody-mediated rejection (AMR) have thus far limited the expansion of ABO incompatible (ABOi) kidney transplantation. We present a retrospective review of our single-center experience with 60 consecutive ABOi kidney transplants and describe the evolution of our treatment protocol to one that consists only of a brief escalation in immunosuppression without long-term B-cell suppression from splenectomy or anti-CD20. The 1-, 3-, and 5-year graft survival rates for the cohort were 98.3%, 92.9%, and 88.7%, respectively, which is comparable with United Network for Organ Sharing data for compatible live donor transplants. No instances of hyperacute rejection were observed, and no grafts were lost secondary to AMR. In fact, fewer than 15% of the patients experienced a clinical episode of AMR, and rejections were mild. Elimination of B-cell ablative therapies did not result in an increased incidence of AMR. Excellent graft function persists with a current median creatinine clearance of 60 mL/min. The findings of this study and the relatively simple therapeutic regimen used should facilitate widespread application of ABOi kidney transplantation resulting in one of the most rapid escalations in access to organs in the modern era of kidney transplantation.
Montgomery
Robert A
RA
Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA. rmonty@jhmi.edu
Locke
Jayme E
JE
King
Karen E
KE
Segev
Dorry L
DL
Warren
Daniel S
DS
Kraus
Edward S
ES
Cooper
Matthew
M
Simpkins
Christopher E
CE
Singer
Andrew L
AL
Stewart
Zoe A
ZA
Melancon
J Keith
JK
Ratner
Lloyd
L
Zachary
Andrea A
AA
Haas
Mark
M
D000017:ABO Blood-Group System; D001402:B-Lymphocytes / Q000276:immunology; D001787:Blood Group Incompatibility / Q000453:epidemiology* / Q000628:therapy*; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006388:Hemagglutinins / Q000378:metabolism; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology; D008954:Models, Biological; D016377:Organ Transplantation / Q000706:statistics & numerical data*; D010956:Plasmapheresis; D017741:Survivors; D014181:Transplantation Immunology
D000017:ABO Blood-Group System; D006388:Hemagglutinins; D016756:Immunoglobulins, Intravenous